Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





One thousand wavefront guided treatment on microscan visum

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Photoablation Outcomes I

Session Date/Time: Monday 07/09/2015 | 16:30-18:30

Paper Time: 16:42

Venue: Room 17

First Author: : M.Yablokov RUSSIA

Co Author(s): :                        

Abstract Details

Purpose:

Purpose. To determine the predictability, efficacy, safety, and stability of LASIK with the Microscan Visum 500 Hz excimer laser platform and IRX3 Imagine Eyes wavefront aberrometer.

Setting:

Kostroma Ophthalmology Clinic “Eye Surgery”, Russia

Methods:

1021 eyes of 535 patients underwent LASIK for myopia using the PlatoScan™ individualized laser vision correction algorithm that combines the IRX3 Imagine Eyes wavefront and the Microscan Visum Excimer Laser. Refractive outcomes and the change in higher order aberrations, coma, and spherical aberrations were analyzed. Postoperative follow-up ranged from 1 to 6 months.

Results:

Mean postoperative spherical equivalent refraction was 0.02 ± 0.29 diopters (D) (range: – 0.69 to +0.57 D). Uncorrected visual acuity was 1 or better in 960 (94%) eyes and 1.2 or better in 674 (66%) eyes. Postoperative spherical equivalent refraction was within 0.50 D of intended correction in 918 (90%) eyes. The mean cylinder had been reduced to -0.24 ±0.20 D (range: 0.0 to -1.25 D) and 917 (90%) of the eyes had less than 0.5 D of cylinder. 395 eyes (38.7%) gained at least 1 line of corrected distance visual acuity (CDVA), no eyes lost more than 1 line of CDVA.

Conclusions:

Conclusion. Wavefront-guided PlatoScan treatments with the Microscan Visum platform for myopia are safe and effective with excellent visual acuity and refractive outcomes.

Financial Interest:

NONE

Back to previous